Literature DB >> 10419731

Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases.

K Mayerhofer1, A Obermair, G Windbichler, E Petru, A Kaider, L Hefler, K Czerwenka, S Leodolter, C Kainz.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the behavior of uterine leiomyosarcomas in relation to their clinical and pathologic features and to identify possible prognostic factors.
METHODS: Seventy-one patients with histologically proven uterine leiomyosarcoma were included in the analysis. Leiomyosarcomas were defined as uterine smooth-muscle tumors with five or more mitoses per 10 high-power fields and cytologic atypia. Cox proportional hazards regression model was used to identify independent prognostic factors.
RESULTS: The median follow-up time was 108 months; 5-year overall survival rate was 65%. Evaluating the correlation between several clinicopathologic parameters, tumors with vascular space involvement had a statistically significantly higher stage than tumors without vasular space involvement (P = 0.015). In a univariate Cox model early tumor stage (P < 0.0001), age <50 years (P < 0.0001), low mitotic count (P = 0.05), and the absence of vascular space involvement (P < 0.0005) were associated with good prognosis. In a multivariate analysis age (P = 0.002), tumor stage (P = 0.004), vascular space involvement (P = 0.003), and mitotic count in stage I tumors (P = 0.002) were found to be independent parameters for good prognosis in patients with uterine leiomyosarcoma.
CONCLUSION: Early tumor stage, age <50 years, and absence of vascular space involvement were independently associated with good prognosis. Mitotic count was detected to be a strong prognostic parameter in early tumor stage, but failed to act as an independent prognostic parameter in patients with tumor stage II-IV disease. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10419731     DOI: 10.1006/gyno.1999.5436

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  38 in total

1.  A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma.

Authors:  Oliver Zivanovic; Lindsay M Jacks; Alexia Iasonos; Mario M Leitao; Robert A Soslow; Emanuela Veras; Dennis S Chi; Nadeem R Abu-Rustum; Richard R Barakat; Murray F Brennan; Martee L Hensley
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

2.  An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.

Authors:  Mary-Margaret L Allen; Jonathan J Douds; Sharon X Liang; Mohamed M Desouki; Vinita Parkash; Oluwole Fadare
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey.

Authors:  Hideki Tokunaga; Fumiaki Takahashi; Hiroki Yamamoto; Tsuyoshi Honda; Takafumi Watanabe; Tadahiro Shoji; Toru Sugiyama; Hidekazu Yamada; Tomoe Tando; Kosuke Yoshinaga; Satoko Kagabu; Takeo Otsuki; Shogo Kin; Yoshihito Yokoyama; Satoshige Wagatsuma; Kazuyo Sato; Hirokazu Sato; Takashi Oishi; Yuji Yoshida; Tadashi Hayasaka; Toshihiko Matsui; Noriaki Imai; Hidekazu Nishigori; Hiroaki Shimokawa; Nobuo Yaegashi; Yoh Watanabe
Journal:  Int J Clin Oncol       Date:  2017-02-10       Impact factor: 3.402

4.  A Case of Renal Metastasis of Uterine Leiomyosarcoma.

Authors:  Petar Bajic; William S Gange; Robert H Blackwell; Arpeet S Shah; John Biemer; Maria M Picken; Alex Gorbonos
Journal:  Cureus       Date:  2017-07-14

5.  Treatment of recurrent metastatic uterine leiomyosarcoma of the spine: a multimodality approach using resection, radiosurgery, and chemotherapy.

Authors:  Michael J Strong; Trevor Rosenlof; Siddhartha Padmanabha; Roy S Weiner; Lee Roy Morgan; Marcus I Ware
Journal:  J Neurosurg Spine       Date:  2015-07-17

6.  Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas.

Authors:  Kenichi Nakamura; Hiroaki Kajiyama; Fumi Utsumi; Shiro Suzuki; Kaoru Niimi; Ryuichiro Sekiya; Jun Sakata; Eiko Yamamoto; Kiyosumi Shibata; Fumitaka Kikkawa
Journal:  Mol Clin Oncol       Date:  2018-01-19

7.  Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma.

Authors:  Inigo Espinosa; Andrew H Beck; Cheng-Han Lee; Shirley Zhu; Kelli D Montgomery; Robert J Marinelli; Kristen N Ganjoo; Torsten O Nielsen; C Blake Gilks; Robert B West; Matt van de Rijn
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

8.  Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.

Authors:  Kristelle Lusby; Kari Brewer Savannah; Elizabeth G Demicco; Yiqun Zhang; Markus Ph Ghadimi; Eric D Young; Chiara Colombo; Ryan Lam; Tugce E Dogan; Jason L Hornick; Alexander J Lazar; Kelly K Hunt; Matthew L Anderson; Chad J Creighton; Dina Lev; Raphael E Pollock
Journal:  Ann Surg Oncol       Date:  2013-01-20       Impact factor: 5.344

9.  Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors.

Authors:  Bernadette Liegl-Atzwanger; Ellen Heitzer; Karin Flicker; Stephanie Müller; Peter Ulz; Ozlen Saglam; Fattaneh Tavassoli; Mojgan Devouassoux-Shisheboran; Jochen Geigl; Farid Moinfar
Journal:  Mod Pathol       Date:  2016-07-01       Impact factor: 7.842

10.  Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Leiomyosarcoma: 27 Years of Experience.

Authors:  R Rothmund; M Huebner; C Joachim; A Hartkopf; T Fehm; M Bamberg; M Wallwiener; S Brucker; F A Taran
Journal:  Geburtshilfe Frauenheilkd       Date:  2011-12       Impact factor: 2.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.